GnRH Therapy on Cognition in Down Syndrome

Sponsor
Nelly Pitteloud
Study ID
NCT04390646
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Alzheimer Disease, Early Onset
  • Cognitive Decline
  • Down Syndrome
  • Olfaction Disorders

Eligibility Criteria

Sex
ALL
Age
16 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • GnRH, gonadorelin acetate — DRUG
    Drug administered by a subcutaneous pump
  • 0.9% NaCl — DRUG
    Drug administered by a subcutaneous pump

Study Details

Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old. Early Alzheimer's disease (AD) is the most common cause of death within this population. DS individuals already show AD neuropathology by the age of 30, while it becomes clinically recognized in their late forties. DS subjects also exhibit olfaction defects in adulthood. To date, there is no treatment available for the cognitive or olfactory defects in DS. The development of an effective treatment targeting cognitive dysfunction in DS adolescents/adults would be warranted. GnRH, a decapeptide secreted by hypothalamic neurons is the pilot light of reproduction in all mammals. Pulsatile GnRH acts on the gonadotrophs via the GnRH receptor (GNRHR) in the pituitary gland to stimulate LH and FSH, which themselves will act on the gonads to produce gametes and steroids. However, GNRHR are also expressed in cerebral cortex, hippocampus, amygdala, habenula, olfactory structures, and adrenal gland, suggesting that GnRH may have a role beyond reproduction. Recently, GnRH has been shown to be involved in the process of ageing and lifespan control. Notably, in murine models, GnRH acts as an anti-ageing factor, independent of sex hormones. While ageing is characterized by hypothalamic inflammation and diminished neurogenesis, particularly in the hypothalamus and the hippocampus, GnRH was able to promote adult neurogenesis. The regulation of GnRH secretion is complex and involves hormonal, neuronal input, and environmental factors. Prévot et al. recently explored cognition within the Ts65Dn model and showed an age-dependent loss of the ability to recognize new objects. Also, these mice exhibit defects in olfaction. Given the role of GnRH in anti-aging mice model, pulsatile GnRH or continuous GnRH infusion (leading to desensitization of the GNRHR) were given to the Ts65Dn mice for two weeks. Amazingly, pulsatile but not continuous GnRH therapy was able to recover cognitive and olfaction defects.

Key Dates

First listed
May 15, 2020
Start date
Aug 27, 2020
Status verified
Feb 2024
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
56 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Pulsatile GnRH pump treatment
  • Placebo Comparator: Pulsatile placebo pump treatment

Primary Outcome Measure

Cognition [ Time Frame: Baseline to end of treatment (Week 24) ]

Central Contacts

Related Studies